Regeneron Pharmaceuticals (REGN) stock surged 5.06% in pre-market trading on Friday following the release of its impressive second-quarter 2025 financial results. The biotechnology company significantly outperformed analysts' expectations, demonstrating robust growth across key metrics.
Regeneron reported adjusted earnings per share (EPS) of $12.89, handily beating the estimated $8.57. The company's sales for the quarter reached $3.680 billion, surpassing the projected $3.294 billion. This represents a 4% year-over-year revenue growth, showcasing the company's strong market position and effective business strategy.
Several factors contributed to Regeneron's stellar performance. Notably, Dupixent, the company's blockbuster drug, saw its global net sales (recorded by Sanofi) increase by 22% to $4.34 billion. While total EYLEA HD and EYLEA U.S. net sales decreased by 25% to $1.15 billion, EYLEA HD U.S. net sales grew by 29% to $393 million, indicating a shift in product mix. The company also highlighted recent FDA approvals for Lynozyfic and expanded indications for Dupixent, signaling potential for future growth. With these results and ongoing developments, investors appear optimistic about Regeneron's future prospects, driving the pre-market rally.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.